Comparator drug supply for global clinical trials, from Indian WHO-GMP origin.
Phase 2 and Phase 3 trial sponsors and Contract Research Organisations source comparator medicinal products and rescue therapy IMPs from India in volume, against ICH GCP and EU Clinical Trial Regulation requirements. M Care is the manufacturer-side partner for sourcing the comparator at trial-grade documentation, with the dossier and cold-chain that a CRO's clinical supply chain manager actually needs.
Comparator drug. Rescue therapy. Investigational Medicinal Product.
A clinical trial comparing a new molecule against standard-of-care needs a supply of the comparator drug — typically the marketed reference product or its bioequivalent. Sponsors source comparators from the original innovator's commercial chain or, increasingly, from Indian WHO-GMP generic equivalents where a bioequivalence-adequate comparator is acceptable to the trial protocol. The same applies to rescue therapy supply, where a backup IMP must be on-shelf at trial sites against an unanticipated patient need.
Who the route serves
Contract Research Organisations running multi-country Phase 2 and Phase 3 trials, where the comparator must arrive at every site in time-coordinated quantity, with consistent batch and stability profile across sites. Pharmaceutical trial sponsors handling their own clinical supply. Academic coordinating centres on investigator-led trials with funding-constrained comparator budgets.
Where we sit in it
Manufacturer-side. We are not the trial sponsor and we are not a Sponsor-Investigator. We are the Indian WHO-GMP facility's commercial and regulatory arm, sourcing the comparator molecule at trial-grade quality and documentation, with the GCP-aligned attachments the CRO's clinical supply manager files in the trial master file.
What the CRO gets
Comparator product on a validated cold-chain or ambient lane (depending on molecule), with batch-specific CoA, stability data harmonised to the trial protocol's window, randomisation/blinding-compatible packaging where the trial requires it, and an audit trail every regulatory inspection by the FDA, EMA, MHRA or PMDA can drill into.
Why a CRO clinical supply manager phones us.
Innovator comparator pricing
The original innovator's commercial pricing of a 5,000-patient Phase 3 comparator inflates the trial budget past acceptable. An Indian WHO-GMP bioequivalent — where the trial protocol allows generic comparator — typically lands at 30-60% of innovator-commercial cost, with full regulatory documentation.
Multi-country lane consistency
A trial running in 22 countries needs the comparator from the same manufacturer, the same batch series, and the same shelf life across every site. Indian WHO-GMP campaigns can produce a single multi-country batch on a coordinated lane, eliminating the fragmented-batch risk of per-country commercial sourcing.
Rescue therapy on-shelf
Trial protocols increasingly require rescue therapy IMPs to be available at every site against unanticipated patient need. Indian-manufactured rescue therapy supply is the practical answer where the rescue molecule is generic-equivalent and doesn't require innovator-only sourcing.
Re-supply during trial extension
A Phase 3 extension cohort or a follow-on safety study needs continued comparator supply past the original campaign. We re-batch from the same manufacturing partner where the trial protocol requires batch continuity, with stability bridge-data filed against the extension.
Every document a clinical supply manager files in the trial master file.
Prepared at the Indian end and cross-checked before dispatch. ICH GCP-aligned, EU CTR / FDA IND ready, supplied to the CRO's clinical supply chain manager ahead of arrival.
Batch-specific CoA
HPLC assay, related substances, sterility / endotoxin where applicable, packaging integrity. Signed by the manufacturer's QC head. Methods aligned to the trial protocol's quality standards.
Comparator stability data
Stability data covering the trial timeline plus a 12-24 month buffer past the protocol's end date. ICH Q1A-aligned, with the temperature-zone profile matched to the destination trial site's environment.
GCP-aligned manufacturer declaration
Manufacturer's declaration of GCP-aligned production conditions for the comparator batch — covering documentation, traceability, blinding-compatible packaging where the trial requires it, and chain-of-custody from manufacturing line to dispatch.
Bioequivalence and reference data
Where a generic-equivalent comparator is supplied, the bioequivalence study report referenced to the innovator brand's reference. Required by EU CTR Article 51 dossier and increasingly by FDA IND submissions for protocol-defined comparators.
Cold-chain or ambient packaging validation
Pre-shipment thermal validation per shipper configuration (most clinical comparator consignments ship 2-8°C or 15-25°C ambient). Continuous logging in transit. On-arrival logger read-out before the carton is opened by the trial site pharmacy.
Regulatory inspection-ready audit trail
Full chain-of-custody documentation from manufacturing line to dispatch — manufacturing batch records, packaging records, dispatch QA sign-off, courier tracking. Filed in a format the FDA, EMA, MHRA and PMDA inspectors can drill into during a routine CRO inspection.
Molecule · trial countries · patient count · stability window · dispatch schedule.
- Send the protocol-relevant specifics. Comparator molecule (INN), strength, dosage form, total trial-cohort quantity, country split, stability window required, blinding/labelling specification (open / single-blind / double-blind), and the dispatch schedule across trial start-up, randomisation, and follow-on.
- Manufacturer match and quote. We confirm the Indian manufacturing partner whose comparator batch will support the protocol's stability and bioequivalence requirements, batch availability, the BE reference data on file, and a landed price to your CRO's clinical supply chain warehouse.
- GCP-aligned dossier package. CoA, stability data, bioequivalence study report (where applicable), manufacturer declaration, packaging validation, dispatch SOP. Shared electronically for the CRO's clinical supply manager and quality assurance team to review and file in the trial master file.
- Cold-chain or ambient dispatch. Per-site or central-warehouse delivery on a validated lane. Continuous logging where required, on-arrival logger read-out, dispatch confirmation routed to the CRO's site monitor and trial site pharmacy. Re-supply scheduling fixed against the protocol's trial calendar.
- Regulatory inspection support. When the CRO or the sponsor receives a regulatory inspection during or after the trial, we provide source-side documentation — batch records, packaging records, dispatch QA sign-off, manufacturing-site GMP audit reports — to the inspectors via the CRO's quality team. The audit trail is built to be drillable, not summarised.
Clinical trials comparator supply — the specifics.
Are you a CRO, an IMP manufacturer, or a sponsor?
None of the above. We are the Indian manufacturer-side partner. We source the comparator molecule from a WHO-GMP manufacturing partner and supply it with GCP-aligned documentation to the CRO or sponsor's clinical supply chain. The CRO retains responsibility for the trial master file, the sponsor retains responsibility for the IND / CTA submission.
Can you supply blinded / double-blind packaging?
Yes, on a per-protocol basis. Where the trial requires identical-appearance comparator packaging (matched to the investigational arm's packaging), we coordinate at-source over-encapsulation, blister re-packaging or vial re-labelling against the sponsor's blinding specification. Validated packaging room conditions documented.
What's the typical lead time for a multi-country comparator order?
Stock-on-hand molecules: 4-8 weeks from order confirmation to first-site delivery. Manufacture-to-order or campaign-batched comparators: 12-20 weeks. Stability bridge studies for trial extensions: 8-16 weeks elapsed for the bridge data, with the supply itself running on 4-8-week cycles.
Do you supply rescue therapy IMPs?
Yes. Rescue therapy supply is treated as a standing-order line for the trial duration, with quarterly or monthly re-stock dispatches to each site, and on-call escalated supply against unanticipated patient need.
Can you support an EU Clinical Trial Regulation (CTR) submission?
We support the manufacturer-side appendices of an EU CTR Article 51 submission — manufacturing-site GMP, batch records, comparator stability, BE reference data. The sponsor or sponsor-CMC team retains responsibility for the overall CTR submission to EMA via CTIS.
Can you support an FDA IND submission?
Same as above for an FDA IND. We supply manufacturer-side CMC documentation that the sponsor's IND application incorporates. We do not file an IND on behalf of a sponsor.
Which therapeutic areas have you supported on clinical trial comparator supply?
Oncology (cytotoxics and targeted therapies), anti-infectives (antibiotics and antivirals), cardiovascular, CNS-neurology, anaesthesia and ICU, vaccines (where the comparator is a generic-equivalent vaccine). Most active in oncology comparator supply for Phase 2/3 trials.
How do you handle pharmacovigilance for trial-related ADRs?
Trial-related ADR reporting is the sponsor's responsibility under the trial protocol. Where the ADR is potentially attributable to the comparator batch's manufacturing or formulation, we provide manufacturer-side root-cause analysis support — batch records review, manufacturing-site inspection, formulation testing — within the timeline the sponsor's PV team needs.
A multi-country trial, a comparator molecule, a stability window. That's the conversation.
Comparator molecule, trial cohort size, country split, stability window, blinding spec. We'll have a manufacturer-side answer inside one working day.